Abiraterone acetate (Zytiga) may significantly delay progression of pain and quality of life deterioration in patients with metastatic castration-resistant prostate cancer when taken in conjunction with prednisone, according to a new multicenter study.

John Schieszer reports in today’s Medical Minute that this drug combination resulted in a more than eight-month delay in progression of pain, and a more than four-month delay in quality of life deterioration.

Continue Reading